An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.

ABSTRACT:

Background

Live attenuated influenza vaccines (LAIV) against a variety of strains of pandemic potential are being developed and tested. We describe the results of an open-label phase I trial of a live attenuated H2N2 virus vaccine.

Objectives

To evaluate the safety, infectivity, and immunogenicity of a live attenuated H2N2 influenza virus vaccine.

Participants/methods

The A/Ann Arbor/6/60 (H2N2) virus used in this study is the attenuated, cold-adapted, temperature-sensitive strain that provides the genetic backbone of seasonal LAIV (MedImmune). We evaluated the safety, infectivity, and immunogenicity of two doses of 10(7) TCID(50) of this vaccine administered by nasal spray 4 weeks apart to normal healthy seronegative adults.

Results

Twenty-one participants rec

SUBMITTER: Talaat KR 

PROVIDER: S-EPMC3527634 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature